You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Nanotrap particle viral enrichment technology for enabling portal, next-generation sequencing-based surveillance

    SBC: CERES NANOSCIENCES            Topic: NCIRD

    PROJECT SUMMARY RNA viruses, such as influenza and the Ebola virus, have been classified as the greatest threat for causing a global pandemic given their high mutation rates and abilities to jump between host species. National and global agencies have called for research and development efforts to improve RNA virus surveillance capabilities. While the tools for surveilling DNA viruses have advance ...

    SBIR Phase I 2020 Department of Health and Human ServicesCenters for Disease Control and Prevention
  2. Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein

    SBC: BLUEWILLOW BIOLOGICS INC            Topic: NIAID

    ABSTRACTRespiratory syncytial virus (RSV) is extremely ubiquitous, with almost all humans acquiring the infection by the age of two.It is manifested by several secondary acute respiratory illnesses including bronchiolitis croup, bronchitis, pneumonia and the common cold.RSV does not elicit a protective immune response in humans, which results in recurrent infections in children and adults.Infants ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Prodrugs and Derivatives of Hydroxymethylfurfural (5-HMF) to Develop a Novel, Bioavailable Treatment for Sickle Cell Disease

    SBC: IllExcor Therapeutics LLC            Topic: NHLBI

    In this SBIR Phase I project, IllExcor Therapeutics proposes the development and evaluation of novel prodrug therapeutics as a yet untapped approach to treat sickle cell disease (SCD), a hereditary malady involving a single point hemoglobin (Hb) mutation that leads to severe adverse physiological complications culminating in painful vaso-occlusive crises, chronic endothelial damage, and progressiv ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Improving the clarification, characterization, and homogeneity of animal serum through Nanotrap nanoparticle technology

    SBC: CERES NANOSCIENCES            Topic: 400

    PROJECT SUMMARY SARS-CoV-2 is the β-coronavirus causing the current coronavirus disease 2019 (COVID-19) outbreak. Large- scale diagnostic testing and large-scale screening are key tools used to contain outbreaks, and are especially important for something as transmissible as SARS-CoV-2. While various clinical specimens—like blood, pharyngeal swabs, saliva, anal swabs, and urine—have showed th ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a vaccine to prevent Pneumocystis pneumonia

    SBC: NXT BIOLOGICS, INC.            Topic: NIAID

    Despite the fact that fungal diseases are an increasing clinical burden, particularly among immunocompromised patients, there are no anti-fungal vaccines approved for clinical use. The fungal opportunistic pathogen, Pneumocystis jirovecii is the causative agent of Pneumocystis pneumonia (PCP), which remains a serious AIDS-defining, opportunistic infection and is of increasing concern in persons re ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R41/R42- Clinical Trial Optional)

    SBC: BRIGHTLINE INTERACTIVE LLC            Topic: NIDA

    Randamp;R Other Project Information 7. Project Summary/Abstract Neurobiological changes caused by addiction impair behavioral control and increase relapse risk (Volkow, Koob, andamp; McLellan, 2016), substantiating the need for long-term care coordination and recovery engagement for individuals with Substance Use Disorders (SUD) (Humphreys, Malenka, Knutson, andamp; MacCoun, 2017). Because addicti ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Dynamic Breath Gas Sensor (DBGS™) for Detection of Pulmonary Edema

    SBC: EXHALIX LLC            Topic: NHLBI

    Project Summary/Abstract The proposed effort addresses an unmet need for early detection of pulmonary edema (PE). PE is a cardiovascular disorder and is the underlying cause of acute respiratory distress syndrome and acute heart failure, projected to affect more than 8 million Americans by 2030. PE is caused by abnormally high capillary leakage into the alveolar cavities leading to accumulation of ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Blood Vessels

    SBC: PHOTOSONOX LLC            Topic: NEI

    ABSTRACT / PROJECT SUMMARY Wet age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Anti-VEGF therapy is currently the gold standard for wet AMD treatment. However, up to 50% of patients in the long term have a suboptimal response to anti-VEGF therapy. A better alternative method for treatment of AMD is urgently needed. We have recently inve ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a suite of high-specificity fucose binding reagents

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: 300

    PROJECT SUMMARY Glycans have several distinct properties that make them excellent targets for disease biomarkers. Firstly, their location glycans on cell surfaces makes them the first point of contact for cellular interactions, and thus they are crucial in the control of normal metabolic processes. Secondly, cell surface molecules are also strategically exposed for surveillance by the immune syste ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Rifampin potentiation in NTM

    SBC: SpinCeutica, Inc.            Topic: NIAID

    Non-tuberculous mycobacterial lung disease (NTM-LD) caused by Mycobacterium avium complex is a serious chronic infection causing permanent lung damage, and is difficult to treat, typically requiring 12-24 months of treatment with rifampin, macrolide and ethambutol. We hypothesize that combined deuterated ambroxol and [acyl-13C]INH will allow both pharmacokinetic and pharmacodynamic enhancement of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government